Enovis and Schrodinger Stocks Compared

Analysts see more upside potential in Enovis shares compared to Schrodinger

Apr. 5, 2026 at 6:34am

Got story updates? Submit your updates here. ›

Enovis (NYSE:ENOV) and Schrodinger (NASDAQ:SDGR) are both small-cap medical companies, but analysts believe Enovis is the stronger investment. The analysis compares the two companies on factors like valuation, profitability, earnings, risk, analyst recommendations, institutional ownership, and dividends.

Why it matters

This analysis provides investors with a detailed comparison of two promising medical technology companies, helping them make more informed decisions about where to allocate their capital. The findings on factors like institutional ownership, analyst sentiment, and valuation metrics offer valuable insights into the relative strengths and growth potential of Enovis and Schrodinger.

The details

The analysis found that Enovis has stronger institutional ownership at 98.5% compared to Schrodinger's 79.1%. Enovis also has a lower price-to-earnings ratio, indicating it is currently more affordable than Schrodinger. Additionally, Enovis has a higher consensus price target from analysts, suggesting more potential upside. However, Schrodinger has higher insider ownership at 21% versus Enovis' 2.7%.

  • The analysis was published on April 5, 2026.

The players

Enovis Corporation

A medical technology company that develops clinically differentiated solutions for reconstructive surgery, rehabilitation, pain management, and physical therapy.

Schrodinger, Inc.

A company that develops physics-based computational platforms to enable discovery of novel molecules for drug development and materials applications.

Got photos? Submit your photos here. ›

The takeaway

This analysis highlights the relative strengths of Enovis and Schrodinger, with Enovis appearing to have more favorable valuation, institutional backing, and analyst sentiment. Investors looking to gain exposure to the medical technology sector may want to further research these two companies to determine which better fits their investment goals and risk profile.